
SAB BIO R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

DATE: | January 28, 2025 |
---|---|
TIME: | 8:00 AM EST |
LOCATION: | Virtual |
About The Event
Join SAB BIO for a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.
A live question and answer session will follow the formal presentations.